Ramaswamy Govindan

Research output

Research output per year 1992 2008 2010 2015 2018 2020 2021 2022 2023

• 291 Article
• 62 Review article
• 30 Comment/debate
• 17 Letter
• 21 More
  • 10 Editorial
  • 7 Chapter
  • 2 Short survey
  • 1 Book
  • 1 Foreword/postscript

Research output per year

Research output per year

Search results

• 2023

  Author Correction: The landscape of viral associations in human cancers (Nature Genetics, (2020), 52, 3, (320-330), 10.1038/s41588-019-0558-9)

  PCAWG Pathogens & PCAWG Consortium, Jun 2023, In: Nature Genetics. 55, 6, p. 1077 1 p.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • Genome 100%
  • Neoplasms 47%
  • Germany 32%
  • Infections 17%

• Author Correction: Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing (Nature Genetics, (2020), 52, 3, (331-341), 10.1038/s41588-019-0576-7)

  PCAWG-Structural Variation Working Group & PCAWG Consortium, Jun 2023, In: Nature Genetics. 55, 6, p. 1076 1 p.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • Chromothripsis 100%
  • Whole Genome Sequencing 67%
  • Genome 39%
  • Neoplasms 18%

• Author Correction: Comprehensive molecular characterization of mitochondrial genomes in human cancers (Nature Genetics, (2020), 52, 3, (342-352), 10.1038/s41588-019-0557-x)

  PCAWG Consortium, Jun 2023, In: Nature Genetics. 55, 6, p. 1078 1 p.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • Mitochondrial Genome 100%
  • Genome 53%
  • Neoplasms 25%

• Author Correction: Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition (Nature Genetics, (2020), 52, 3, (306-319), 10.1038/s41588-019-0562-0)

  PCAWG-Structural Variation Working Group & PCAWG Consortium, Jun 2023, In: Nature Genetics. 55, 6, p. 1080 1 p.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • Genome 100%
  • Medicine 53%
  • Neoplasms 47%
  • Baltimore 47%
  • Quebec 44%

• Author Correction: Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer (Nature Genetics, (2020), 52, 3, (294-305), 10.1038/s41588-019-0564-y)

  PCAWG-Structural Variation Working Group & PCAWG Consortium, Jun 2023, In: Nature Genetics. 55, 6, p. 1079 1 p.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • Chromatin 100%
  • Genome 76%
  • Neoplasms 36%

• Author Correction: Pan-cancer analysis of whole genomes (Nature, (2020), 578, 7793, (82-93), 10.1038/s41586-020-1969-6)

  The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, Feb 16 2023, In: Nature. 614, 7948, p. E39

  Research output: Contribution to journal › Comment/debate

  Open Access

  • Genome 100%
  • Neoplasms 47%
  1 Scopus citations
• 2022

  Author Correction: High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations (Nature Communications, (2020), 11, 1, (736), 10.1038/s41467-019-13885-w)

  PCAWG Transcriptome Working Group, PCAWG-Structural Variation Working Group, PCAWG Consortium, Appelbaum, E. L., Aukema, S., Fulton, L. A., Fulton, R. S., Jayasinghe, R., Ley, T., Miller, C. A., Mutch, D. & Wendl, M. C., Dec 1 2022, In: Nature communications. 13, 1, 7572.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • genome 100%
  • Gene Rearrangement 89%
  • genes 89%
  • cancer 71%
  • Communication 69%

• Author Correction: Divergent mutational processes distinguish hypoxic and normoxic tumours (Nature Communications, (2020), 11, 1, (737), 10.1038/s41467-019-14052-x)

  PCAWG Consortium, Fulton, L. A., Fulton, R. S., Govindan, R., Jayasinghe, R., Ley, T., Miller, C. A., Mutch, D. & Wendl, M. C., Dec 2022, In: Nature communications. 13, 1, 7569.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • genome 100%
  • document markup languages 91%
  • tumors 73%
  • cancer 71%
  • Communication 69%
  1 Scopus citations

• Author Correction: Combined burden and functional impact tests for cancer driver discovery using DriverPower (Nature Communications, (2020), 11, 1, (734), 10.1038/s41467-019-13929-1)

  PCAWG Drivers and Functional Interpretation Working Group, PCAWG Consortium, Fulton, L. A., Fulton, R. S., Govindan, R., Jayasinghe, R., Ley, T., Miller, C. A., Mutch, D. & Wendl, M. C., Dec 1 2022, In: Nature communications. 13, 1, 7571.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • impact tests 100%
  • genome 79%
  • cancer 71%
  • Communication 69%
  • communication 63%

• Author Correction: Integrative pathway enrichment analysis of multivariate omics data (Nature Communications, (2020), 11, 1, (735), 10.1038/s41467-019-13983-9)

  PCAWG Drivers and Functional Interpretation Working Group, PCAWG Consortium, Fulton, L. A., Fulton, R. S., Govindan, R., Jayasinghe, R., Ley, T., Miller, C. A., Mutch, D. & Wendl, M. C., Dec 1 2022, In: Nature communications. 13, 1, 7570.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • genome 100%
  • document markup languages 91%
  • cancer 71%
  • Communication 69%
  • communication 63%

• Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns (Nature Communications, (2020), 11, 1, (728), 10.1038/s41467-019-13825-8)

  PCAWG Tumor Subtypes and Clinical Translation Working Group, PCAWG Consortium, Fulton, L. A., Fulton, R. S., Govindan, R., Jayasinghe, R., Ley, T., Miller, C. A., Mutch, D. & Wendl, M. C., Dec 2022, In: Nature communications. 13, 1, 7573.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • Deep Learning 100%
  • genome 94%
  • passengers 93%
  • document markup languages 86%
  • mutations 84%

• Author Correction: Pathway and network analysis of more than 2500 whole cancer genomes (Nature Communications, (2020), 11, 1, (729), 10.1038/s41467-020-14367-0)

  PCAWG Drivers and Functional Interpretation Working Group, PCAWG Consortium, Appelbaum, E. L., Fulton, L. A., Fulton, R. S., Govindan, R., Jayasinghe, R., Ley, T., Miller, C. A., Mutch, D. & Wendl, M. C., Dec 1 2022, In: Nature communications. 13, 1, 7566.

  Research output: Contribution to journal › Comment/debate

  Open Access

• Author Correction: Genomic footprints of activated telomere maintenance mechanisms in cancer (Nature Communications, (2020), 11, 1, (733), 10.1038/s41467-019-13824-9)

  PCAWG-Structural Variation Working Group, PCAWG Consortium, Borst, C., Fulton, L. A., Fulton, R. S., Jayasinghe, R., Ley, T., Miller, C. A., Mutch, D. & Wendl, M. C., Dec 1 2022, In: Nature communications. 13, 1, 7574.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • telomeres 100%
  • genome 76%
  • document markup languages 70%
  • footprints 66%
  • Telomere 64%

• Author Correction: Inferring structural variant cancer cell fraction (Nature Communications, (2020), 11, 1, (730), 10.1038/s41467-020-14351-8)

  PCAWG Evolution and Heterogeneity Working Group, PCAWG Consortium, Fulton, L. A., Fulton, R. S., Govindan, R., Jayasinghe, R., Ley, T., Miller, C. A., Mutch, D. & Wendl, M. C., Dec 1 2022, In: Nature communications. 13, 1, 7568.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • genome 100%
  • cancer 71%
  • Communication 69%
  • document markup languages 68%
  • communication 63%

• Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment (Nature Communications, (2021), 12, 1, (5086), 10.1038/s41467-021-25177-3)

  The NCI PDXNet Consortium, Dec 2022, In: Nature communications. 13, 1, 294.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • Communication 100%
  • Heterografts 98%
  • communication 90%
  • Income 90%
  • light emitting diodes 87%

• Author Correction: Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig (Nature Communications, (2020), 11, 1, (731), 10.1038/s41467-020-14352-7)

  PCAWG Evolution and Heterogeneity Working Group, PCAWG Consortium, Fulton, L. A., Fulton, R. S., Govindan, R., Jayasinghe, R., Ley, T., Miller, C. A., Mutch, D. & Wendl, M. C., Dec 1 2022, In: Nature communications. 13, 1, 7567.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • genome 100%
  • document markup languages 91%
  • mutations 89%
  • cancer 71%
  • Communication 69%
• 2021

  Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts (Nature Genetics, (2021), 53, 1, (86-99), 10.1038/s41588-020-00750-6)

  PDXNET Consortium & EurOPDX Consortium, May 2021, In: Nature Genetics. 53, 5, p. 761 1 p.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • Licensure 100%
  • Heterografts 82%
  • Neoplasms 29%
  4 Scopus citations

• Erratum: Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway (Cell Reports (2021) 34(5), (S2211124721000206), (10.1016/j.celrep.2021.108707))

  TCGA Research Network, Feb 23 2021, In: Cell Reports. 34, 8, 108784.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • Adenocarcinoma of Lung 100%
  • Emotions 73%
  • Error 69%
  • Genome 63%
  4 Scopus citations
• 2020

  Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (Nature Communications, (2020), 11, 1, (4748), 10.1038/s41467-020-18151-y)

  MC3 Working Group, PCAWG novel somatic mutation calling methods working group & PCAWG Consortium, Dec 1 2020, In: Nature communications. 11, 1, 6232.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • genome 100%
  • Exome 92%
  • mutations 89%
  • medicine 82%
  • cancer 71%

• Mastering the Complex Targeted Therapy for Non-small Cell Lung Cancer

  Devarakonda, S., Govindan, R. & Morgensztern, D., Sep 14 2020, In: Cancer Cell. 38, 3, p. 320-322 3 p.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • High-Throughput Nucleotide Sequencing 100%
  • Non-Small Cell Lung Carcinoma 93%
  • Lung 55%
  • Genes 41%
  • Therapeutics 17%
  5 Scopus citations

• The Mystic Role of Tumor Mutational Burden in Selecting Patients with Lung Cancer for First-Line Immunotherapy

  Waqar, S. N. & Govindan, R., May 2020, In: JAMA oncology. 6, 5, p. 674-675 2 p.

  Research output: Contribution to journal › Comment/debate
  6 Scopus citations
• 2019

  Biomarker-Driven Staging-Are We There Yet?

  Devarakonda, S. & Govindan, R., Dec 2 2019, In: JAMA Network Open. 2, 12, p. e1917052

  Research output: Contribution to journal › Comment/debate

  Open Access

• Erratum: The Immune Landscape of Cancer (Immunity (2018) 48(4) (812–830.e14), (S1074761318301213), (10.1016/j.immuni.2018.03.023))

  The Cancer Genome Atlas Research Network, Aug 20 2019, In: Immunity. 51, 2, p. 411-412 2 p.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • Immunity 100%
  • Names 77%
  • Genes 49%
  • Neoplasms 39%
  • Research Design 32%
  167 Scopus citations

• Untangling the evolutionary roots of lung cancer

  Devarakonda, S. & Govindan, R., Dec 1 2019, In: Nature communications. 10, 1, 2979.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • lungs 100%
  • cancer 86%
  • Non-Small Cell Lung Carcinoma 82%
  • Lung Neoplasms 72%
  • progressions 51%
  12 Scopus citations
• 2018

  Erratum: Comprehensive Characterization of Cancer Driver Genes and Mutations (ARTICLE (2018) 173(2) (371–385), (S009286741830237X), (10.1016/j.cell.2018.02.060))

  The MC3 Working Group, The Cancer Genome Atlas Research Network, The MC3 Working Group & The Cancer Genome Atlas Research Network lding@wustl.edu, Aug 9 2018, In: Cell. 174, 4, p. 1034-1035 2 p.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • Neoplasm Genes 100%
  • Mutation 77%
  • Adenocarcinoma 72%
  • ethyl-2-methylthio-4-methyl-5-pyrimidine carboxylate 48%
  • Error 34%
  233 Scopus citations

• Erratum: The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (Cell Reports (2018) 23(1) (313–326.e5) (S2211124718304364) (10.1016/j.celrep.2018.03.075))

  The Cancer Genome Atlas Research Network, Jun 19 2018, In: Cell Reports. 23, 12, p. 3698 1 p.

  Research output: Contribution to journal › Comment/debate

  Open Access

  • Atlases 100%
  • Renal Cell Carcinoma 89%
  • Names 88%
  • Emotions 73%
  • Error 69%
  86 Scopus citations
• 2014

  Summary report from the 13^th annual targeted therapies of the treatment of lung cancer meeting

  Morgensztern, D. & Govindan, R., Jan 2014, In: Clinical Lung Cancer. 15, 1, p. 16-20 5 p.

  Research output: Contribution to journal › Comment/debate
  1 Scopus citations
• 2011

  Erratum: Biostatistics primer: What a clinician ought to know: Hazard ratios (Journal of Thoracic Oncology (2011) 6 (978-982))

  Barraclough, H., Simms, L. & Govindan, R., Aug 2011, In: Journal of Thoracic Oncology. 6, 8, p. 1454 1 p.

  Research output: Contribution to journal › Comment/debate

  Open Access
• 2010

  One more fallen star-ZODIAC and its implications

  Stinchcombe, T. E. & Govindan, R., Jul 2010, In: The Lancet Oncology. 11, 7, p. 604-605 2 p.

  Research output: Contribution to journal › Comment/debate
  3 Scopus citations
• 1997

  Erratum: Practical issues in the management of the patient with small cell lung cancer (Chest Surgery Clinics of North America (February 1997) (174))

  Govindan, R. & Idhe, D. C., 1997, In: Chest Surgery Clinics of North America. 7, 3, p. 174 1 p.

  Research output: Contribution to journal › Comment/debate